MarketPeel
Insider Trading Intelligence
Pricing
…
TH

Tony W. Ho

CRSP
EXECUTIVE VP, HEAD OF R&D · CRISPR THERAPEUTICS AG · CIK 0001713637
FILING MIX · LIFETIME40%/60%
BUYS
12
SELLS
18
TOTAL VALUE
$6.32M
COMPANIES
1
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
52,364
AVG SELL PX
$107.11
TRADE KIND
SHOWING 30 / 30
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
13 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Tony W. Ho, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d13+15.38%+0.64%+1.03%-0.39%+0.08%—
14d13+84.62%-1.94%+1.56%-3.50%-5.55%—
30d13+0.00%+14.68%+4.37%+10.32%+9.39%—
60d13+69.23%+1.48%+6.97%-5.49%-16.73%—
90d13+69.23%-6.90%+8.06%-14.95%-27.36%—
180d13+69.23%+10.44%+15.59%-5.15%-36.92%—
1y13+69.23%-13.25%+31.45%-44.69%-79.66%—
2y13+100.00%-55.68%+15.37%-71.05%-80.90%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRSP · 52,364 shares · as of Dec 6, 2021
059,112118,225177,337236,4492021SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
FLOW · 12 buys / 18 sellsCOVERAGE · 8 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILED
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
12,607$69.17$872.0K52,364Dec 6, 2021Dec 7, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Executive VP, Head of R&D
26,667——64,971Dec 3, 2021Dec 7, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Executive VP, Head of R&D
26,667——13,333Dec 3, 2021Dec 7, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
13,800——13,800Oct 15, 2021Oct 18, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
9,000——9,000Mar 11, 2021Mar 12, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
23,334——23,334Mar 11, 2021Mar 12, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Executive VP, Head of R&D
4,583——40,445Mar 10, 2021Mar 12, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
2,141$124.15$265.8K38,304Mar 10, 2021Mar 12, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
1,585$114.65$181.7K35,862Mar 5, 2021Mar 9, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Executive VP, Head of R&D
3,333——37,447Mar 5, 2021Mar 9, 2021 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
1,400$147.05$205.9K50,315Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
1,100$151.58$166.7K52,215Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
500$152.41$76.2K51,715Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
1,700$148.11$251.8K55,815Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
2,951$150.61$444.5K33,964Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
1,600$150.16$240.3K53,315Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
23,551——236,449Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Executive VP, Head of R&D
23,551$16.90$398.0K57,515Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
900$149.18$134.3K54,915Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
5,000$149.73$748.6K36,915Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
8,400$148.38$1.25M41,915Dec 21, 2020Dec 22, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
16,666——16,666Oct 5, 2020Oct 6, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
6,929$75.20$521.1K33,747Jun 23, 2020Jun 24, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
229$70.14$16.1K40,676Jun 22, 2020Jun 24, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
6,100$70.14$427.9K40,905May 26, 2020May 27, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
600$70.05$42.0K47,005May 22, 2020May 27, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
13,750——13,750Mar 10, 2020Mar 12, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASEGRANT
Stock grant
55,000——55,000Mar 10, 2020Mar 12, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
SALE
Executive VP, Head of R&D
1,563$52.64$82.3K47,605Mar 6, 2020Mar 9, 2020 ↗
CRSP
CRISPR THERAPEUTICS AG
PURCHASE
Executive VP, Head of R&D
3,333——49,168Mar 5, 2020Mar 9, 2020 ↗
Other insiders · CRSP
Loading peer insiders…
About this filer
CIK 0001713637
ROLE
Executive VP, Head of R&D
PRIMARY
CRSP
COMPANIES
1
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001713637DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback